207 related articles for article (PubMed ID: 17270482)
1. [Anogenital warts incidence, medical management and costs in women consulting gynaecologists in France].
Monsonégo J; Breugelmans JG; Bouée S; Lafuma A; Bénard S; Rémy V
Gynecol Obstet Fertil; 2007 Feb; 35(2):107-13. PubMed ID: 17270482
[TBL] [Abstract][Full Text] [Related]
2. Epidemiology and cost of treatment of genital warts in Spain.
Castellsagué X; Cohet C; Puig-Tintoré LM; Acebes LO; Salinas J; San Martin M; Breitscheidel L; Rémy V
Eur J Public Health; 2009 Jan; 19(1):106-10. PubMed ID: 19112075
[TBL] [Abstract][Full Text] [Related]
3. Determining the cost of genital warts: a study from Ireland.
Dee A; Howell F; O'Connor C; Cremin S; Hunter K
Sex Transm Infect; 2009 Sep; 85(5):402-3. PubMed ID: 19004863
[TBL] [Abstract][Full Text] [Related]
4. Assessing incidence and economic burden of genital warts with data from a US commercially insured population.
Hoy T; Singhal PK; Willey VJ; Insinga RP
Curr Med Res Opin; 2009 Oct; 25(10):2343-51. PubMed ID: 19650749
[TBL] [Abstract][Full Text] [Related]
5. The incidence of genital warts in Australian women prior to the national vaccination program.
Brotherton JM; Heywood A; Heley S
Sex Health; 2009 Sep; 6(3):178-84. PubMed ID: 19653953
[TBL] [Abstract][Full Text] [Related]
6. Estimation of the incidence of genital warts and the cost of illness in Germany: a cross-sectional study.
Hillemanns P; Breugelmans JG; Gieseking F; Bénard S; Lamure E; Littlewood KJ; Petry KU
BMC Infect Dis; 2008 Jun; 8():76. PubMed ID: 18518976
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France.
Bergeron C; Largeron N; McAllister R; Mathevet P; Remy V
Int J Technol Assess Health Care; 2008; 24(1):10-9. PubMed ID: 18218164
[TBL] [Abstract][Full Text] [Related]
8. Human papillomavirus, genital warts, and vaccines.
Hsueh PR
J Microbiol Immunol Infect; 2009 Apr; 42(2):101-6. PubMed ID: 19597640
[TBL] [Abstract][Full Text] [Related]
9. Impact of the human papillomavirus (HPV) vaccine on genital wart diagnoses at Auckland Sexual Health Services.
Oliphant J; Perkins N
N Z Med J; 2011 Jul; 124(1339):51-8. PubMed ID: 21952330
[TBL] [Abstract][Full Text] [Related]
10. [Quality of life of patients with condyloma].
Mortensen GL; Larsen HK
Ugeskr Laeger; 2008 Nov; 170(47):3858-62. PubMed ID: 19014739
[TBL] [Abstract][Full Text] [Related]
11. The health and economic burden of genital warts in a set of private health plans in the United States.
Insinga RP; Dasbach EJ; Myers ER
Clin Infect Dis; 2003 Jun; 36(11):1397-403. PubMed ID: 12766834
[TBL] [Abstract][Full Text] [Related]
12. Cost of treatment and QALYs lost due to genital warts: data for the economic evaluation of HPV vaccines in the United Kingdom.
Woodhall SC; Jit M; Cai C; Ramsey T; Zia S; Crouch S; Birks Y; Newton R; Edmunds WJ; Lacey CJ
Sex Transm Dis; 2009 Aug; 36(8):515-21. PubMed ID: 19543143
[TBL] [Abstract][Full Text] [Related]
13. Economic burden associated with the management of cervical cancer, cervical dysplasia and genital warts in Belgium.
Annemans L; Rémy V; Lamure E; Spaepen E; Lamotte M; Muchada JP; Largeron N
J Med Econ; 2008; 11(1):135-50. PubMed ID: 19450115
[TBL] [Abstract][Full Text] [Related]
14. Treatment patterns and associated costs for genital warts in Italy.
Merito M; Largeron N; Cohet C; Timelli L; Boselli F; Matteelli A; Naldi L; Vittori G
Curr Med Res Opin; 2008 Nov; 24(11):3175-83. PubMed ID: 18851777
[TBL] [Abstract][Full Text] [Related]
15. Medical Care Costs Associated with Genital Warts for Commercially Insured US Patients.
Dahlstrom KR; Fu S; Chan W; Shelal Z; Ramondetta LM; Lairson DR
Pharmacoeconomics; 2018 Nov; 36(11):1355-1365. PubMed ID: 30019118
[TBL] [Abstract][Full Text] [Related]
16. Genital warts incidence and healthcare resource utilisation in Australia.
Pirotta M; Stein AN; Conway EL; Harrison C; Britt H; Garland S
Sex Transm Infect; 2010 Jun; 86(3):181-6. PubMed ID: 19965802
[TBL] [Abstract][Full Text] [Related]
17. Quadrivalent human papillomavirus vaccine.
Barr E; Tamms G
Clin Infect Dis; 2007 Sep; 45(5):609-7. PubMed ID: 17682997
[TBL] [Abstract][Full Text] [Related]
18. The burden of genital warts: a study of nearly 70,000 women from the general female population in the 4 Nordic countries.
Kjaer SK; Tran TN; Sparen P; Tryggvadottir L; Munk C; Dasbach E; Liaw KL; Nygård J; Nygård M
J Infect Dis; 2007 Nov; 196(10):1447-54. PubMed ID: 18008222
[TBL] [Abstract][Full Text] [Related]
19. Epidemiology and costs associated with genital warts in Canada.
Marra F; Ogilvie G; Colley L; Kliewer E; Marra CA
Sex Transm Infect; 2009 Apr; 85(2):111-5. PubMed ID: 18981170
[TBL] [Abstract][Full Text] [Related]
20. The new human papillomavirus (HPV) vaccine: pros and cons for pediatric and adolescent health.
Thomas TL
Pediatr Nurs; 2008; 34(5):429-31. PubMed ID: 19051848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
